Nomura Raises WUXI APPTEC's Target Price to HKD157.07; Anticipates Higher Revenue This Year
Positive Profit Alert: WUXI APPTEC has issued a profit alert estimating a 9.2% increase in revenue and a 142% increase in net profit for Q4 2025, reaching RMB11.7 billion and RMB7.1 billion, respectively.
FY26 Revenue Forecast: For FY26, WUXI APPTEC's revenue is expected to grow by 16% YoY to RMB52.6 billion, surpassing market expectations, while earnings are projected to rise by 3% YoY to RMB19.6 billion.
Target Price Increase: Nomura has raised WUXI APPTEC's target price from HKD132.8 to HKD157.07 and maintains a Buy rating on the stock.
Market Context: The healthcare sector in China is increasingly relying on data and earnings visibility, with a positive outlook for CDMO firms, according to G Sachs.
Trade with 70% Backtested Accuracy
Analyst Views on 02359
About the author
M Stanley Publishes Thematic Focus List Highlighting High Conviction Opportunities in APAC (Table)
Stock Performance: TSMC and Tencent saw positive gains, with Tencent increasing by 2.246%, while Samsung Electronics and NAURA experienced declines.
Short Selling Data: Significant short selling activity was noted, with TENCENT at a ratio of 13.981% and PING AN at 32.071%, indicating investor caution.
Market Insights: CLSA recommends Contract Development and Manufacturing Organizations (CDMOs) for their earnings visibility, highlighting WUXI APPTEC, WUXI BIO, and PHARMARON as top picks.
Market Delays: Stock quotes for Hong Kong and A Shares are delayed by at least 15 minutes, affecting real-time trading information.
<Research>CLSA Prefers CDMOs for Earnings Clarity, Recommends WUXI APPTEC, WUXI BIO, and PHARMARON as Top Choices
AI Impact on CRO/CDMO Sector: Investors are shifting focus towards AI disintermediating middlemen, with expectations that integrated CRDMO platforms will benefit more from AI than specialized CROs, which may face mixed effects from internal AI adoption.
CDMO Preference: CLSA favors CDMOs over CROs for better earnings visibility due to their capacity locking capabilities and long-term projects, with WUXI APPTEC, WUXI BIO, and PHARMARON highlighted as top picks in the sector.
M Stanley Raises Price Target for WUXI APPTEC (02359.HK) to HKD143.5, Maintains Overweight Rating
Earnings Forecast Update: Morgan Stanley has raised its earnings forecast for WUXI APPTEC for 2026-30 by 0-3% due to increased gross margins, adjusting the target price from HKD143 to HKD143.5.
Growth Potential: The broker assigned an Overweight rating to WUXI APPTEC, predicting a 24% CAGR for its earnings from 2024-27, citing its unique CRDMO/CTDMO model and a strong pipeline of early-stage projects as key growth drivers.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
<Daily Summary> HSI Ends at 27,032, Dropping 233 Points; HSTI Finishes at 5,408, Decreasing by 91 Points; MEITUAN Falls More Than 4%; WUXI APPTEC, SHK PPT, SINOPEC CORP, CHINA RES MIXC, HK & CHINA GAS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 233 points (0.9%) to close at 27,032, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Meituan, Tencent, and Xiaomi saw significant drops, with Meituan down 4.5% and Tencent down 2.3%, amidst high short selling activity.
Notable Movers: Bud APAC and Lenovo Group faced substantial losses, with Bud APAC down 5.2%, while Zijin Mining and PICC P&C were among the few gainers, with Zijin Mining up 3.4%.
High Performers: Unisound and Guofuhee experienced remarkable gains, with Unisound rising by 16.8%, indicating strong market interest in these stocks.
HSI Drops 242 Points at Midday, Driven by Technology Stocks; CN Developers and WUXI Series Surge
Market Performance: Hong Kong stocks faced a decline, with the HSI dropping 242 points (0.9%) to 27,023, while the HSCEI and HSTECH also fell by nearly 1% and 1.7%, respectively.
Tech Stocks Struggles: Major tech companies like NTES, BABA, and TENCENT saw significant drops in their share prices, with NTES down 3.8% and BABA down 2.1%, amid disappointing earnings reports and ongoing investment strategies.
Chinese Developers' Gains: Some Chinese developers, including CHINA VANKE and RONSHINECHINA, experienced gains due to reports of a potential RMB80 billion rescue package from the Shenzhen municipal government.
WUXI APPTEC's Success: WUXI APPTEC emerged as the best-performing blue chip, rising nearly 4% after Nomura raised its revenue expectations and target price, indicating strong future performance.
M Stanley Publishes Thematic Focus List Highlighting High Conviction Opportunities in APAC (Table)
Stock Performance: TSMC and Tencent saw positive gains, with Tencent increasing by 2.246%, while Samsung Electronics and NAURA experienced declines.
Short Selling Data: Significant short selling activity was noted, with TENCENT at a ratio of 13.981% and PING AN at 32.071%, indicating investor caution.
Market Insights: CLSA recommends Contract Development and Manufacturing Organizations (CDMOs) for their earnings visibility, highlighting WUXI APPTEC, WUXI BIO, and PHARMARON as top picks.
Market Delays: Stock quotes for Hong Kong and A Shares are delayed by at least 15 minutes, affecting real-time trading information.
<Research>CLSA Prefers CDMOs for Earnings Clarity, Recommends WUXI APPTEC, WUXI BIO, and PHARMARON as Top Choices
AI Impact on CRO/CDMO Sector: Investors are shifting focus towards AI disintermediating middlemen, with expectations that integrated CRDMO platforms will benefit more from AI than specialized CROs, which may face mixed effects from internal AI adoption.
CDMO Preference: CLSA favors CDMOs over CROs for better earnings visibility due to their capacity locking capabilities and long-term projects, with WUXI APPTEC, WUXI BIO, and PHARMARON highlighted as top picks in the sector.
M Stanley Raises Price Target for WUXI APPTEC (02359.HK) to HKD143.5, Maintains Overweight Rating
Earnings Forecast Update: Morgan Stanley has raised its earnings forecast for WUXI APPTEC for 2026-30 by 0-3% due to increased gross margins, adjusting the target price from HKD143 to HKD143.5.
Growth Potential: The broker assigned an Overweight rating to WUXI APPTEC, predicting a 24% CAGR for its earnings from 2024-27, citing its unique CRDMO/CTDMO model and a strong pipeline of early-stage projects as key growth drivers.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
<Daily Summary> HSI Ends at 27,032, Dropping 233 Points; HSTI Finishes at 5,408, Decreasing by 91 Points; MEITUAN Falls More Than 4%; WUXI APPTEC, SHK PPT, SINOPEC CORP, CHINA RES MIXC, HK & CHINA GAS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 233 points (0.9%) to close at 27,032, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Meituan, Tencent, and Xiaomi saw significant drops, with Meituan down 4.5% and Tencent down 2.3%, amidst high short selling activity.
Notable Movers: Bud APAC and Lenovo Group faced substantial losses, with Bud APAC down 5.2%, while Zijin Mining and PICC P&C were among the few gainers, with Zijin Mining up 3.4%.
High Performers: Unisound and Guofuhee experienced remarkable gains, with Unisound rising by 16.8%, indicating strong market interest in these stocks.
HSI Drops 242 Points at Midday, Driven by Technology Stocks; CN Developers and WUXI Series Surge
Market Performance: Hong Kong stocks faced a decline, with the HSI dropping 242 points (0.9%) to 27,023, while the HSCEI and HSTECH also fell by nearly 1% and 1.7%, respectively.
Tech Stocks Struggles: Major tech companies like NTES, BABA, and TENCENT saw significant drops in their share prices, with NTES down 3.8% and BABA down 2.1%, amid disappointing earnings reports and ongoing investment strategies.
Chinese Developers' Gains: Some Chinese developers, including CHINA VANKE and RONSHINECHINA, experienced gains due to reports of a potential RMB80 billion rescue package from the Shenzhen municipal government.
WUXI APPTEC's Success: WUXI APPTEC emerged as the best-performing blue chip, rising nearly 4% after Nomura raised its revenue expectations and target price, indicating strong future performance.
